Sugi Predict

Sugi Predict / Compounds / SCHEMBL4010743

SCHEMBL4010743

SCHEMBL4010743

C[Si](C)(C)CCOCn1nc(-c2nc3ccccc3[nH]2)c2cc(NS(=O)(=O)c3ccccc3S(C)(=O)=O)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 6/20 0.40
▸ RAB9A P51151 5/20 0.40
▸ KMT2A Q03164 5/20 0.40
▸ MMP2 P08253 1/20 0.37
▸ MMP9 P14780 1/20 0.37
▸ MMP8 P22894 1/20 0.37
▸ MMP13 P45452 1/20 0.37
▸ PDPK1 O15530 1/20 0.35
▸ MEN1 O00255 4/20 0.35
▸ MAPT P10636 5/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ HPGD P15428 1/20 0.34
▸ BRD4 O60885 4/20 0.34
▸ LMNA P02545 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ GAA P10253 2/20 0.33
▸ TSHR P16473 2/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ SIRT1 Q96EB6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4005684 0.79 NR1I2 (0.37) NPC1KMT2AMEN1MAPTALDH1A1
SCHEMBL7507932 0.79 SMN1; SMN2 (0.38) NPC1RAB9AKMT2APDPK1MEN1
SCHEMBL3515746 0.79 SMN1; SMN2 (0.42) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL4007070 0.78 MEN1 (0.35) NPC1KMT2AMEN1MAPTHPGD
SCHEMBL3515959 0.77 MMP2 (0.47) NPC1RAB9AKMT2AMMP2MMP9
SCHEMBL14493377 0.76 SMN1; SMN2 (0.49) NPC1RAB9AKMT2APDPK1MEN1
SCHEMBL14493604 0.75 ACHE (0.39) NPC1RAB9AKMT2AMAPTALDH1A1
SCHEMBL4003411 0.74 PDPK1 (0.59) NPC1RAB9AKMT2APDPK1
SCHEMBL5509018 0.74 SMN1; SMN2 (0.34) NPC1RAB9AMAPTALDH1A1SMN1; SMN2
SCHEMBL5516821 0.73 CDK1 (0.47) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473701-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2009-01-06 — — US disclosed
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-03-17 — — US disclosed
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 — — US disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 NPC1 3050/4885RAB9A 2902/4885KMT2A 1089/4885
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 NPC1 3386/4885RAB9A 2870/4885KMT2A 1222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.